NSPR
InspireMD, Inc.
NASDAQ · Healthcare · Medical - Devices · IL
$0.85
+1.26%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-1.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| May 29, 2026 | Stuka Paul · director | Purchase | 20,000 | $0.88 |
| May 21, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 7,186 | $2.51 |
| May 21, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 5,132 | $2.46 |
| May 21, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 9,923 | $2.55 |
| May 21, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 10,000 | $3.65 |
| May 21, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 3,760 | $2.51 |
| May 21, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 7,073 | $2.51 |
| May 21, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 2,941 | $1.59 |
| May 21, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 2,454 | $2.51 |
| May 21, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 1,572 | $2.51 |
| May 21, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 3,660 | $2.46 |
| May 21, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 2,476 | $2.61 |
| May 21, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 22,778 | $1.01 |
| May 21, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 3,858 | $2.71 |
| May 21, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 2,482 | $2.51 |
| May 15, 2026 | Stuka Paul · director | Purchase | 10,000 | $1.16 |
| May 15, 2026 | Stuka Paul · director | Purchase | 5,000 | $1.15 |
| May 13, 2026 | Slosman Marvin · director, officer: CEO and President | Purchase | 21,000 | $1.20 |
| May 12, 2026 | Stuka Paul · director | Purchase | 10,000 | $1.19 |
| May 12, 2026 | Stuka Paul · director | Purchase | 65,626 | $1.16 |
| May 8, 2026 | Stuka Paul · director | Purchase | 6,378 | $1.15 |
| May 8, 2026 | ROUBIN GARY S · director | Purchase | 90,000 | $1.18 |
| May 8, 2026 | Ward Scott R. · director | Purchase | 73,255 | $1.15 |
| May 8, 2026 | Ward Scott R. · director | Purchase | 15,995 | $1.15 |
| May 8, 2026 | Stuka Paul · director | Purchase | 1,517 | $1.12 |
| Feb 2, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 5,000 | $1.65 |
| Feb 2, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 12,395 | $1.65 |
| Feb 2, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 4,781 | $1.66 |
| Feb 2, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 8,411 | $1.57 |
| Feb 2, 2026 | Gleason Shane Thomas · officer: Chief Commercial Officer | Sale | 17,593 | $1.62 |
Institutional positioning
13F filings over the trailing two quarters
New 4Increased 4Reduced 11Sold out 35
| Filer | Action | Shares | Filed |
|---|---|---|---|
| ROSALIND ADVISORS, INC. | Unchanged | 3,905,743 | May 14, 2026 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | Unchanged | 3,376,484 | May 15, 2026 |
| ABRDN PLC | Unchanged | 3,173,364 | Apr 29, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 3,133,405 | May 15, 2026 |
| PARKMAN HEALTHCARE PARTNERS LLC | Unchanged | 2,416,518 | May 15, 2026 |
| VELAN CAPITAL INVESTMENT MANAGEMENT LP | Reduced | 2,099,652 | May 15, 2026 |
| MARSHALL WACE, LLP | Unchanged | 1,860,405 | May 15, 2026 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | Reduced | 1,045,708 | May 14, 2026 |
| PURA VIDA INVESTMENTS, LLC | Unchanged | 450,517 | May 12, 2026 |
| INGALLS & SNYDER LLC | Reduced | 379,300 | May 13, 2026 |
| AFFIANCE FINANCIAL, LLC | Unchanged | 250,370 | Apr 14, 2026 |
| ESSEX INVESTMENT MANAGEMENT CO LLC | Unchanged | 114,085 | May 11, 2026 |
| MILLENNIUM MANAGEMENT LLC | Reduced | 112,423 | May 15, 2026 |
| BLACKROCK, INC. | Increased | 80,449 | May 13, 2026 |
| CITADEL ADVISORS LLC | Reduced | 65,750 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing May 29, 2026